Compare TG Therapeutics Inc (TGTX) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tractor Supply Co — how do they compare? TG Therapeutics Inc trades at $54.98 (market cap $8.16B), while Tractor Supply Co trades at $33.64 (market cap $17.44B). The key difference: Tractor Supply Co is far larger — about 2.1× TG Therapeutics Inc's market cap, and Tractor Supply Co pays a 2.87% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Tractor Supply Co for 89 Days on average.
| TGTX | TSCO | |
|---|---|---|
Market Cap | $8.16B | $17.44B |
Volume | 1,735,121 | 10,598,723 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $56.37 |
52-Week Low | $26.94 | $29.14 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $8.37B | $23.76B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Tractor Supply (TSCO) trades at $33.64, up 3.43% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $15.52B in 2025, though net income margin has declined to 6.42%. Recent earnings have missed expectations, and cash flow trends show variability. The company maintains a strong dividend streak and continues community investments, as highlighted in recent news.
The outlook is mixed: analyst consensus is a Buy with a $36.76 target, but consecutive earnings misses and margin pressure pose risks. Upside hinges on execution amid cyclical challenges, while institutional selling and competitive threats warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
